title: Incidence of hypercalcemia, hypercalciuria and related factors in patients treated with recombinant human parathyroid hormone (1-84).
abstract: OBJECTIVE
  The aim of this paper was to determine the incidence of hypercalcemia and hypercalciuria (and related factors) in 22 postmenopausal women with osteoporosis treated with PTH (1-84) in daily practice.
  
  
  METHODS
  Osteoporosis was defined as history of osteoporotic fracture or a T score less than -3 SD on bone densitometry. Patients were treated with PTH (1-84), 100 mcg/daily, for 12 months. Clinical and laboratory data at baseline and after 6 months of treatment were assessed.
  
  
  RESULTS
  The mean age was 71.9 years. The incidence of hypercalcemia and the hypercalciuria were 6 events. Increase in serum calcium levels showed a statistically significant correlation with 24-hour urinary calcium (rho [ρ]=0.83, P<0.001), serum alkaline phosphatase (ρ=0.76, P=0.001), total proteins (ρ=0.77, P=0.005), and β-CTx (ρ=0.82, P=0.002). On the other hand, 24-hour urinary calcium excretion correlated significantly with β-CTx (ρ=0.83, P=0.002), alkaline phosphatase (ρ=0.73, P=0.005), total proteins (ρ=0.73, P=0.02), and serum phosphate (ρ=0.58, P=0.04). When the group of patients with and without hypercalcemia were compared, there were statistically significant differences in increases of β-CTx and baseline β-CTx values, whereas the group of patients with and without hypercalciuria showed significant differences in serum calcium increases and baseline values of T score at the femoral neck.
  
  
  CONCLUSIONS
  The incidence of hypercalcemia and hypercalciuria after treatment with PTH (1-84) is similar to that expected according to the product's technical specifications. There was a significant correlation between increases of serum calcium, urinary calcium excretion, serum alkaline phosphatase, and β-CTx after treatment with PTH (1-84). Baseline β-CTx values were significantly lower in patients who developed hypercalcemia than in those with normal serum calcium levels.
authors.affiliation: Unit of Clinical Management of the Locomotor System and Rehabilitation, Service of of Physical Medicine and Rehabilitation, Infanta Margarita Hospital, Cabra, Córdoba, Spain. francisco.luna.cabrera.sspa@juntadeandalucia.es
authors.forename: F
authors.initials: F
authors.lastname: Luna-Cabrera
authors.forename: E A
authors.initials: EA
authors.lastname: Justicia-Rull
authors.forename: M P
authors.initials: MP
authors.lastname: Caricol-Pérez
authors.forename: E
authors.initials: E
authors.lastname: Soler-Vizán
authors.forename: C M
authors.initials: CM
authors.lastname: Mesa-López
authors.forename: M A
authors.initials: MA
authors.lastname: Ruiz-Ruiz
authors.forename: L E
authors.initials: LE
authors.lastname: De La Torre-López
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced / Q000453:epidemiology*; D053565:Hypercalciuria / Q000139:chemically induced / Q000453:epidemiology*; D015994:Incidence; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000009:adverse effects / Q000627:therapeutic use*; D010710:Phosphates / Q000097:blood; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology; D018709:Statistics, Nonparametric
chemical_list: D010281:Parathyroid Hormone; D010710:Phosphates; D011994:Recombinant Proteins; D000469:Alkaline Phosphatase